A group of advanced practice providers discuss treatment options for a woman with newly diagnosed, transplant-ineligible ...

Olaparib after surgery resulted in durable response rates in patients with high-risk biochemically recurrent prostate cancer ...

Panelists discuss how the care team identifies and manages symptoms in chronic graft-versus-host disease patients, particularly those with advanced disease, emphasizing key symptoms to monitor, ...

Earlier switch to atezolizumab after run-in with vemurafenib plus cobimetinib showed promise in improving OS rates in BRAF ...

During a Community Case Forum series, breast cancer experts discussed the importance of testing for ESR1 mutations, in ...

NKT2152, a novel HIF2a inhibitor, demonstrates significant efficacy in patients with advanced clear cell renal cell carcinoma ...

The FDA approved isatuximab plus bortezomib, lenalidomide, and dexamethasone for patients with newly diagnosed myeloma who ...

The Food and Drug Administration approved ribociclib plus an aromatase inhibitor for hormone receptor (HR)–positive, ...

Nivolumab, given with or without ipilimumab, showed durable 10-year survival outcomes in patients with advanced melanoma.

While none of the experimental combinations met efficacy targets, durvalumab with monalizumab and ceralasertib showed ...

Adjuvant durvalumab failed to improve disease-free survival in resected EGFR- or ALK-negative non-small cell lung cancer.

Breastfeeding is feasible for patients with hormone receptor–positive breast cancer who are undergoing a break of endocrine ...